ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
Retrieved on:
Wednesday, March 8, 2023
Janus, MD, SAN, Atopic dermatitis, AA, Hair loss, Skin, KOL, IP, Granuloma annulare, ASLN, Yale University, Scalp, JAK, Vitiligo, Yale School of Medicine, Patient, Associate, Autoimmune disease, Hair, DHODH, Immune privilege, Lichen planus, Alopecia areata, Sarcoidosis, Pharmaceutical industry, Dermatology
Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.
Key Points:
- Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.
- ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
- A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN’s website .
- He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders.